The Procter & Gamble Company (PG) FY2026 8-K Filings and Company Events

Filings that contain financial statements

The following 8-K exhibits carry full income statement, balance sheet, and cash-flow-statement tables. Because P&G's fiscal year ends June 30, its April-June quarter is never covered by a quarterly report, so only the July 29, 2026 exhibit sources figures used elsewhere in this record, specifically the unaudited fourth-quarter figures; the annual periods (FY2026/FY2025/FY2024) come from the FY2026 Form 10-K (accession 0000080424-26-000103) and the January-March quarter comes from the Form 10-Q (accession 0000080424-26-000060). The October 2025 and January 2026 exhibits below are not the source of any figure referenced outside this file:

• Accession 0000080424-25-000240 (filed October 24, 2025), Exhibit 99.1 earnings release for the quarter ended September 30, 2025 (fiscal Q1 2026). Contains condensed consolidated statement of cash flows, condensed consolidated balance sheet, segment results, and non-GAAP reconciliations.
• Accession 0000080424-26-000006 (filed January 22, 2026), Exhibit 99.1 earnings release for the quarter ended December 31, 2025 (fiscal Q2 2026). Contains the same set of statements.
• Accession 0000080424-26-000056 (filed April 24, 2026), Exhibit 99.1 earnings release for the quarter ended March 31, 2026 (fiscal Q3 2026). Contains the same set of statements.
• Accession 0000080424-26-000093 (filed July 29, 2026), Exhibit 99.1 earnings release for the quarter and fiscal year ended June 30, 2026 (fiscal Q4/full-year 2026). Contains full-year consolidated earnings information, cash flow statement, and balance sheet alongside the fourth-quarter figures.

Earnings and guidance

October 24, 2025, Fiscal Q1 2026 results (accession 0000080424-25-000240). Net sales of $22.4 billion, up 3%; organic sales up 2%. Diluted EPS $1.95 (+21%, largely reflecting prior-year restructuring charges tied to the Argentina market exit); core EPS $1.99 (+3%). Operating cash flow was $5.4 billion and adjusted free cash flow productivity was 102%. The company returned $3.8 billion to shareowners ($2.55 billion dividends, $1.25 billion buybacks). Full-year fiscal 2026 guidance was maintained: all-in sales growth of 1%-5%, organic sales growth of flat to +4%, diluted EPS growth of 3%-9%, and core EPS growth of flat to +4%.

January 22, 2026, Fiscal Q2 2026 results (accession 0000080424-26-000006). Net sales of $22.2 billion, up 1%; organic sales flat. Diluted EPS $1.78, down 5% versus the prior year on higher restructuring charges; core EPS $1.88, unchanged. Operating cash flow was $5.0 billion; the company returned $4.8 billion to shareowners ($2.5 billion dividends, $2.3 billion buybacks). P&G cut its fiscal 2026 GAAP diluted EPS growth guidance to a range of 1%-6%, down from the prior 3%-9%, reflecting higher non-core restructuring charges; core EPS growth guidance (flat to +4%) and sales-growth guidance were maintained.

April 24, 2026, Fiscal Q3 2026 results (accession 0000080424-26-000056). Net sales of $21.2 billion, up 7%; organic sales up 3%. Diluted EPS $1.63, up 6%, driven in part by a gain on the dissolution of the Glad joint-venture business; core EPS $1.59, up 3%. Operating cash flow was $4.0 billion; the company returned $3.2 billion to shareowners ($2.5 billion dividends, over $600 million buybacks). Full-year sales and EPS growth guidance ranges were maintained, but the company said it now expects fiscal 2026 EPS results to come in toward the lower end of the guidance range, citing increased investment in innovation and demand creation.

July 29, 2026, Fiscal Q4 and full-year 2026 results (accession 0000080424-26-000093). Fourth-quarter net sales were $21.2 billion, up 2%, with organic sales flat; diluted EPS was $1.26, down 15% year over year, and core EPS was $1.43, down 3%, on higher SG&A and lower gross margin. Full fiscal-year 2026 net sales were $87.0 billion, up 3%; organic sales up 1%. Full-year diluted EPS was $6.62, up 2%, and core EPS was $6.89, up 1% (currency-neutral core EPS flat), even as full-year operating income fell 3.4% to $19.75 billion on narrower gross and operating margins. Fiscal 2026 operating cash flow was $19.6 billion and net earnings were $16.1 billion, with adjusted free cash flow productivity of 100%. The company returned more than $15 billion to shareowners for the year ($10.2 billion dividends, $5.0 billion buybacks), its 70th consecutive year of dividend increases and 136th consecutive year of dividend payments. Under the Focused Portfolio, Supply Chain and Productivity Plan announced in June 2025, P&G expects total non-core restructuring costs, that is, costs above the normal ongoing level of restructuring, which the 10-K separately puts at $250-500 million annually, of $1.0-$1.6 billion before tax over a two-year period, with more than half incurred in fiscal 2026 and the remainder expected in fiscal 2027. (The 10-K's Note 3 states total before-tax restructuring costs for the same plan at approximately $1.5-$2.0 billion over the same two-year period; MD&A explains that this figure includes the ongoing program.)

P&G issued initial fiscal 2027 guidance alongside the fourth-quarter results: all-in sales growth of 1%-3%, organic sales growth of 1%-3% (including a 30-50 basis point headwind from brand and product-line discontinuations), diluted EPS growth of 1%-5%, and core EPS growth of flat to +3% versus fiscal 2026 core EPS of $6.89. The company cited an estimated $0.56 per share of combined headwinds for fiscal 2027 from higher commodity, energy, transportation, interest and other costs, plus unfavorable foreign exchange.

Same-day informational slide decks accompanying each earnings release (accessions 0000080424-25-000243, 0000080424-26-000009, 0000080424-26-000057, and 0000080424-26-000097) were furnished under Item 7.01 and reiterate the figures and guidance disclosed in the corresponding earnings-release exhibits; they contain no additional material disclosures.

Capital actions, dividends

• January 13, 2026 (accession 0000080424-26-000002): Board declared a quarterly dividend of $1.0568 per share, payable February 17, 2026, unchanged from the prior quarter.
• April 14, 2026 (accession 0000080424-26-000048): Board declared an increased quarterly dividend of $1.0885 per share (a 3% increase), payable May 15, 2026, marking the 70th consecutive year P&G has raised its dividend and the 136th consecutive year of dividend payments since incorporation in 1890.
• July 14, 2026 (accession 0000080424-26-000082): Board declared a quarterly dividend of $1.0885 per share, payable August 17, 2026, unchanged from the April increase.

Capital actions, debt issuance

• November 3, 2025 (accession 0001193125-25-262609): P&G closed an underwritten public offering of €500 million of 2.900% notes due November 2033 and €500 million of 3.650% notes due November 2045, together with $750 million of 4.100% notes due November 2032 and $500 million of 4.350% notes due November 2035, all under its existing shelf registration statement.
• November 4, 2025 (accession 0001193125-25-264728): P&G closed an additional underwritten public offering of $258,889,000 of floating rate notes due November 2075, also under the existing shelf registration.

M&A, subsequent event

• August 4, 2026 (disclosed in Note 15, Subsequent Event, of the FY2026 Form 10-K, accession 0000080424-26-000103; no 8-K was filed for this event): The Company entered into an agreement to acquire Thorne, a premium wellness and supplement brand in the vitamins, minerals and supplements category, for $3.8 billion. This is signed and pending, not closed, the 10-K states the transaction is anticipated to close in the second quarter of fiscal year 2027, "with the timing subject to regulatory approval and customary closing conditions."

Management changes

• December 9, 2025 (accession 0000080424-25-000287, filed December 15, 2025): Jennifer Davis, Chief Executive Officer - Health Care, notified the company of her intent to retire effective June 30, 2026, after more than 33 years of service.
• July 29, 2026 (accession 0000080424-26-000094): P&G announced that Jon R. Moeller will retire as Executive Chairman and step down from the Board effective July 31, 2026, and will leave the company entirely effective August 14, 2026, after 38 years of service (having previously served as CEO, COO and CFO). Shailesh G. Jejurikar, President and Chief Executive Officer, was appointed Chairman of the Board effective August 1, 2026, in addition to his existing role. The non-employee directors reappointed Joseph Jimenez as independent Lead Director.